An investigational glypican-3–directed CAR T-cell therapy engineered to express IL-15 and IL-21 produced a complete response lasting at least 1 year in a child with chemotherapy-resistant metastatic hepatoblastoma.
Publication|Articles|June 17, 2024
Pharmacy Practice in Focus: Oncology
- June 2024
- Volume 6
- Issue 4
Drug Shortages in Community Oncology: Ensuring Access to Chemotherapy
Persistent chemotherapy drug shortages challenge oncology providers. American Oncology Network employs a drug shortage committee for organized shortage management that involves pharmacists and interdisciplinary stakeholders.
Advertisement
Advertisement
Abstract
Related to this article
Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
Increasingly, pharmacists are leading the obesity management team.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.
EMBER-3 data show switching to the combination at progression nearly doubled PFS versus imlunestrant alone in ESR1-mutated advanced breast cancer.
Target Trial Emulation Finds Limited Survival Benefit With Statins After Colorectal Cancer Treatment
Statin initiation after colorectal cancer treatment was associated with only modest survival differences after investigators accounted for biases that can exaggerate benefits in observational research.
Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.
Advertisement
Advertisement